Strategic leadership Recent leadership changes with Richard Lindstrom, MD as Founder & Chairman signal a renewed focus and credibility in addressing unmet Dry Eye needs, presenting a door for strategic partnerships, advisory roles, and pilot programs with eye care clinics and ophthalmology networks.

Pipeline leverage Three proprietary drug candidates using Klarity delivery offer differentiated clinical advantages, presenting opportunities to position Surface Ophthalmics as a partner for co-development, licensing discussions, and strategic collaborations with larger pharma or specialty ophthalmology players.

Financial runway Capital of $47M combined with a sub-$1M revenue profile indicates a growth-stage company open to partnerships, grant-funded programs, milestone-driven deals, and early-access agreements to expand pipeline reach while conserving capital.

Market focus Specialization in ocular diseases with a clear Dry Eye emphasis and a differentiated delivery platform positions the company to target ophthalmology practices, dry eye clinics, and regional distributors looking to differentiate offerings with novel therapeutics.

Engagement channels Existing tech stack and digital presence including Cloudflare, WordPress, Shopify, Google Cloud, and email marketing enable scalable outreach to clinicians, KOLs, and distributors; this supports targeted campaigns, product education, and onboarding programs for respective partners.